touchIMMUNOLOGY had the great pleasure of speaking with Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) about new treatments for chronic pruritus and prurigo.
Her presentation entitled ‘New treatments for chronic pruritus and prurigo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct.
Disclosures: Prof. Sonja Ständer has acted as an investigator for Dermasence, Galderma, Kiniksa, Menlo, Trevi, Novartis, Sanofi and Vanda. She has also received consultancy/ advisory board/ speaker fees from Abbvie, Almirall, Beiersdorf, Bellus Health, Benevolent, Bionorica, Cara, Clexio, Escient, Galderma, Grünenthal, Kiniksa, Leo, Lilly, Menlo, Pfizer, Sanofi, Trevi, P.G. Unna Academy and Vifor.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
Share this Video
Related Videos In Dermatological Diseases
Jonathan A Bernstein, EAACI 2022: Findings from the Phase 2b Extension Study of Ligelizumab in Chronic Spontaneous Urticaria
Ligelizumab is a monoclonal anti-immunoglobulin (Ig) E antibody that has been investigated in the treatment of chronic spontaneous urticaria. touchIMMUNOLOGY were delighted to speak with Prof. Jonathan A Bernstein (University of Cincinnati; Bernstein Allergy Group & Bernstein Clinical Research Center, Cincinnati, OH, USA) around the aims, design and findings from the phase 2b extension study […]
Ana Maria Giménez-Arnau, EAACI 2022: A Phase 2b Study of Remibrutinib for Chronic Spontaneous Urticaria
Remibrutinib is an oral BTK inhibitor currently being investigated in a phase 2 trial in urticaria. It was a pleasure to talk with Prof. Ana Maria Giménez-Arnau (Hospital del Mar. IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain) around the safety findings from the long term extension of a phase 2b study of remibrutinib in chronic […]
Ana Maria Giménez-Arnau, EAACI 2022: Pathology and Unmet Needs in Chronic Spontaneous Urticaria
It was a pleasure to talk with Prof. Ana Maria Giménez-Arnau (Hospital del Mar. IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain) to discuss the unmet needs in the treatment of chronic spontaneous urticaria and the rationale for investigating remibrutinib in this indication. The abstract ‘Long-term safety and tolerability of remibrutinib (LOU064) in Phase 2b study […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!